Coffee may reduce risk of breast cancer recurrence
the ONA take:
According to a new study, researchers at Lund University and Skane University Hospital in Sweden have found that coffee inhibits the growth of tumors and reduces the risk of recurrence in women with breast cancer treated with tamoxifen.
For the study, researchers analyzed data from 1,090 patients with breast cancer. They found that among the over 500 women who were treated with the estrogen receptor antagonist tamoxifen, those who drank at least two cups of coffee per day had half the risk of disease recurrence compared with those who drank less coffee or no coffee.
The study also showed that women who drank at least two cups per day had smaller breast tumors and fewer hormone-dependent tumors.
"If you like coffee and are also taking tamoxifen, there is no reason to stop drinking it. Just two cups a day is sufficient to make a difference," said study researchers.
Coffee inhibits the growth of tumors and reduces the risk of recurrence in women with breast cancer treated with tamoxifen.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|